Eganelisib (IPI-549) is a highly selective PI3Kγ inhibitor (≥ 150-fold compared with class I PI3K isoforms and other kinases) with anti-tumor activity alone and has shown feasibility when combined with a programmed cell death 1/programmed cell death ligand 1 (PD1/PDL1) inhibitor in preclinical studies. This evidence concerns the gene PIK3CD and neoplasm.